606144-04-1

Basic information

• Product Name: 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-1-Methyl-1H-benzo[d]iMidazole-6-carboxylic acid
• Synonyms: 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-1-Methyl-1H-benzo[d]iMidazole-6-carboxylic acid;6-(4-broMo-2-chlorophenylaMino)-7-fluoro-3-Methyl-3H-benzo[d]iMidazole-5-carboxylic acid;6-(4-Bromo-2-chlorophenylamino)-7-fluoro-3-methyl-benzimidazole-5-carboxylic acid;1H-BenziMidazole-6-carboxylic acid,5-[(4-broMo-2-chlorophenyl)aMino]-4-fluoro-1-Methyl-;6-(4-bromo-2-chloroanilino)-7-fluoro-3-methylbenzimidazole-5-carboxylic acid
• CAS NO: 606144-04-1
• Molecular Formula: C₁₅H₁₀BrClFN₃O₂
• Molecular Weight: 398.6142032
• Mol File: 606144-04-1.mol

Chemical Properties

• Boiling Point: 507.6±60.0 °C(Predicted)
• Appearance: /
• Density: 1.75±0.1 g/cm3(Predicted)
• PKA: 4.18±0.10(Predicted)
• CAS DataBase Reference: 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-1-Methyl-1H-benzo[d]iMidazole-6-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-1-Methyl-1H-benzo[d]iMidazole-6-carboxylic acid(606144-04-1)
• EPA Substance Registry System: 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-1-Methyl-1H-benzo[d]iMidazole-6-carboxylic acid(606144-04-1)

Safety Data

• Hazardous Substances Data: 606144-04-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
5-(4-bromo-2-chlorophenylamino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid is used as a research compound for exploring its potential biological activity and applications in drug development. Its unique structure with multiple substituents may offer novel interactions with biological targets, warranting further investigation into its therapeutic potential.
Used in Medicinal Chemistry Applications:
In the field of medicinal chemistry, 5-(4-bromo-2-chlorophenylamino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid serves as a reference standard or a starting material for the synthesis of new compounds with potential pharmaceutical properties. Its solubility in aqueous solutions and structural features make it a valuable tool for assessing the activity of related compounds and optimizing their pharmacological profiles.
Used in Biological Assays:
5-(4-bromo-2-chlorophenylamino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid is utilized in biological assays to evaluate its interactions with various biological targets and its effects on cellular processes. The presence of the carboxylic acid and amino groups may allow for the compound to modulate specific signaling pathways or enzyme activities, providing insights into its potential therapeutic applications.
Used in Drug Design and Optimization:
As a benzoimidazole derivative with multiple functional groups, 5-(4-bromo-2-chlorophenylamino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid is employed in drug design and optimization processes. Its structural complexity and potential reactivity make it a promising candidate for the development of new drugs with improved efficacy, selectivity, and pharmacokinetic properties.
Used in Chemical Synthesis:
5-(4-bromo-2-chlorophenylamino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid is used as a key intermediate in the synthesis of other complex organic compounds, particularly those with potential applications in the pharmaceutical industry. Its unique structure and functional groups can be further modified or used as a building block for the creation of novel molecules with desired properties.

Upstream product

• 1000340-06-6 methyl 5-[(4-bromophenyl)amino]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylate 
• 606093-58-7 4-Amino-3-fluoro-5-nitro-2-phenylamino-benzoic acid methyl ester 
• 918321-20-7 methyl 5-amino-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylate 
• 31928-47-9 4-bromo-2-chloroiodobenzene 
• 606144-02-9 methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylate 
• 917980-15-5 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carbonitrile 
• 606093-59-8 7-Fluoro-6-phenylamino-3H-benzoimidazole-5-carboxylic acid methyl ester 
• 284030-58-6 4-Amino-2,3-difluoro-5-nitro-benzoic acid methyl ester 
• 61079-72-9 2,3,4,-trifluorobenzoic acid 
• 606143-46-8 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 
• 284030-57-5 4-amino-2,3-difluoro-5-nitro-benzoic acid 
• 197520-71-1 2,3,4-trifluoro-5-nitro-benzoic acid 

Downstream Products

• 606143-52-6 selumetinib 
• 606144-05-2 5-[(4-bromo-2-chlorophenyl)amino]-N-[2-(ethenyloxy)ethoxy]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxamide 

Relevant articles and documents

Synthesis method of semetinib

The invention relates to a synthesis method of simetinib. According to the method, diethoxymethane is creatively adopted as a ring closing reactant, and two-step reaction of ring closing reaction and methylation is combined into one step, so the yield is

Method for preparing semetinib

The invention relates to a method for preparing an MEK1/2 inhibitor smeltinib, which comprises the following steps: carrying out three-step reaction on the synthetic route to synthesize the smeltinib, carrying out post-treatment on the synthetic method wi

Substituted benzimidazole compound and composition with compound

The invention provides a substituted benzimidazole compound and a composition with the compound. The substituted benzimidazole compound is a compound of formula (I) as shown in the specification, or apharmaceutically acceptable salt, prodrug, aquo-complex or solvent compound, polycrystalline type compound, stereisomer or isotope variant of the compound. The compound provided by the invention canbe adopted to treat and/or prevent related diseases caused by MEK (Methyl Ethyl Ketone), such as excessive proliferative diseases, pancreatitis, kidney illness, blastocyte cell transplantation and angiogenesis or angiopoiesis related diseases.

INTERMEDIATES OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MAP2K OR MEK) INHIBITORS AND PROCESS FOR THEIR PREPARATION

The present invention relates to intermediates of Mitogen-activated protein kinase kinase (MAP2K or MEK) inhibitors such as Selumetinib, Binimetinib and process for their preparation. The present invention also relates to process for the 5 preparation of MEK inhibitors such as Selumetinib, and Binimetinib.

PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS

Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-1 and their synthetic intermediates: wherein Z, X1, X2, X5, R2 and R10 are as defined herein. Compounds of Formula Ia-1 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.

NOVEL HYDROGEN SULFATE SALT

The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation. Compound I

SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS

Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-2 and their synthetic intermediates: wherein X1, X2, X5, R1, R2 and R4 are as defined herein. Compounds of Formula Ia-2 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.

N3 alkylated benzimidazole derivatives as MEK inhibitors

Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.